Attralus Overview
- Founded
-
2019

- Status
-
Private
- Employees
-
17

- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$116M
- Investors
-
12
Attralus General Information
Description
Developer of immunotherapies and an imaging diagnostic platform designed for multiple systemic amyloid disease treatment. The company specializes in the research and development of immunotherapies to clear amyloid fibrils in patients with systemic amyloid diseases, like a light chain(AL), transthyretin (ATTR), and LECT2 (ALECT2) amyloidosis, enabling the healthcare industry to treat amyloidosis patients in an efficient manner.
Contact Information
Website
www.attralus.com
Formerly Known As
Aurora Bio
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Primary Office
- 50 Francisco Street
- Suite 450
- San Francisco, CA 94133
- United States
+1 (415) 000-0000
Attralus Timeline
Attralus Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Early Stage VC (Series B) | 08-Sep-2021 | $116M | 00000 | 00000 | Completed | Clinical Trials - Phase 2 |
2. Early Stage VC (Series A) | 14-Sep-2020 | 000.00 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 2 |
1. Accelerator/Incubator | 08-Nov-2019 | Completed | Clinical Trials - Phase 2 |
Attralus Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | 00,000,000 | 00.000000 | 00.00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series A | 00,000,000 | 00.000000 | 00.00 | 00.0 | 00.0 | 00 | 00.0 | 00.00 |
Attralus Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of immunotherapies and an imaging diagnostic platform designed for multiple systemic amyloid disease treatment
Drug Discovery
San Francisco, CA
17
As of 2022
00000
0000
0000-00-00
00000000000
00000
Attralus Competitors (4)
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 0000 | 00.000 |
00000000 000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 - | 00000 |
000000 00000000000 | Formerly VC-backed | Bordentown, NJ | 000.00 | 000000&0 | 000.00 | |
000 0000000 | Venture Capital-Backed | Barcelona, Spain | 00 | 000.00 | 00000 00000 | 000.00 |
Attralus Patents
Attralus Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220160831-A1 | Sap fc fusion proteins and methods of use | Pending | 02-Nov-2020 | 000000000 |
Attralus Executive Team (6)
Attralus Board Members (6)
Name | Representing | Role | Since |
---|---|---|---|
Alexander Denner Ph.D | Sarissa Capital Management | Board Member | 000 0000 |
Corey Goodman Ph.D | venBio | Chairman | 000 0000 |
Jacob Bauer | Self | Board Member | 000 0000 |
Nancy Miller-Rich | Self | Board Member | 000 0000 |
Rahul Kakkar MD | Self | Board Member | 000 0000 |
Attralus Signals
Attralus Investors (12)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|---|---|---|---|---|
Citadel Enterprise Americas | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Janus Henderson Investors | Asset Manager | Minority | 000 0000 | 000000 0 | |
LifeSci Venture Partners | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
Logos Capital | Hedge Fund | Minority | 000 0000 | 000000 0 | |
Redmile Group | Hedge Fund | Minority | 000 0000 | 000000 0 |